The binding of synthetic triiodo l-thyronine analogs to human transthyretin: Molecular basis of cooperative and non-cooperative ligand recognition

Journal of Structural Biology

Volumn 173, Issue 2, 2011, Pages 323-332

  Trivella, Daniela B B ^a   Sairre, Mirela I ^b   Foguel, Debora ^c   Lima, Luis Mauricio T R ^c   Polikarpov, Igor ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Crystal structure; GC 1; GC 24; Isothermal titration calorimetry; T3 analogs; Thyroid hormone receptor beta selective agonist; V30M mutant TTR; Wild type TTR

Indexed keywords

BINDING PROTEIN; GC 24; LIGAND; LIOTHYRONINE; PREALBUMIN; SOBETIROME; THYROID HORMONE; THYROID HORMONE RECEPTOR BETA; THYROMIMETIC AGENT; THYROXINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; HORMONE BINDING; HUMAN; IN VITRO STUDY; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN INTERACTION;

ACETIC ACIDS; BENZHYDRYL COMPOUNDS; CALORIMETRY; HUMANS; PHENOLS; PREALBUMIN; THYROID HORMONE RECEPTORS BETA; TRIIODOTHYRONINE; X-RAY DIFFRACTION;

EID: 78751574007     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2010.10.003     Document Type: Article

References (49)

1. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., Mccoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
2. Amorim B.S., Ueta C.B., Freitas B.C., Nassif R.J., Gouveia C.H., Christoffolete M.A., Moriscot A.S., Lancelloti C.L., Llimona F., Barbeiro H.V., De Souza H.P., Catanozi S., Passarelli M., Aoki M.S., Bianco A.C., Ribeiro M.O. A TRbeta-selective agonist confers resistance to diet-induced obesity. J. Endocrinol. 2009, 203:291-299.
3. Andrea T.A., Cavalieri R.R., Goldfine I.D., Jorgensen E.C. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980, 19:55-63.
4. Andricopulo, A.D., Guido, R.V.C., Trivella, D.B.B., Polikarpov, I., Leitão, A., Montanari, C.A. Recent Trends in Structure-Based Drug Design and Energetics. In: Abraham, D.J. (Ed.), Burger's Medicinal Chemistry, Drug Discovery, vol. 2, seventh ed. John Wiley & Sons, Inc., New York, 2010, pp. 685-724.
5. Bartalena L., Robbins J. Thyroid hormone transport proteins. Clin. Lab Med. 1993, 13:583-598.
6. Borngraeber S., Budny M.J., Chiellini G., Cunha-Lima S.T., Togashi M., Webb P., Baxter J.D., Scanlan T.S., Fletterick R.J. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Nat. Acad. Sci. USA 2003, 100:15358-15363.
7. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763.
8. Cheng S.Y. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev. Endocr. Metab. Disord. 2000, 1:9-18.
9. Cheng S.Y., Pages R.A., Saroff H.A., Edelhoch H., Robbins J. Analysis of thyroid hormone binding to human serum prealbumin by 8-anilinonaphthalene-1-sulfonate fluorescence. Biochemistry 1977, 16:3707-3713.
10. Choi S., Connelly S., Reixach N., Wilson I.A., Kelly J.W. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nat. Chem. Biol. 2010, 6:133-139.
11. Choi S., Reixach N., Connelly S., Johnson S.M., Wilson I.A., Kelly J.W. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J. Am. Chem. Soc. 2010, 132:1359-1370.
12. Connelly S., Choi S., Johnson S.M., Kelly J.W., Wilson I.A. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol. 2010, 20:54-62.
13. Connors L.H., Richardson A.M., Theberge R., Costello C.E. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 2000, 7:54-69.
14. Dundas J., Ouyang Z., Tseng J., Binkowski A., Turpaz Y., Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006, 34:W116-118.
15. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
16. Green N.S., Foss T.R., Kelly J.W., Genistein A natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Nat. Acad. Sci. USA 2005, 102:14545-14550.
17. Grover G.J., Egan D.M., Sleph P.G., Beehler B.C., Chiellini G., Nguyen N.H., Baxter J.D., Scanlan T.S. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3, 5, 3′-triiodo-L-thyronine. Endocrinology 2004, 145:1656-1661.
18. Guimaraes B.G., Sanfelici L., Neuenschwander R.T., Rodrigues F., Grizolli W.C., Raulik M.A., Piton J.R., Meyer B.C., Nascimento A.S., Polikarpov I. The MX2 macromolecular crystallography beamline: a wiggler X-ray source at the LNLS. J. Synchrotron. Radiat. 2009, 16:69-75.
19. Hamilton J.A., Steinrauf L.K., Braden B.C., Liepnieks J., Benson M.D., Holmgren G., Sandgren O., Steen L. The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30->Met variant to 1.7-A resolution. J. Biol. Chem. 1993, 268:2416-2424.
20. Hammarstrom P., Wiseman R.L., Powers E.T., Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299:713-716.
21. Johansson L., Rudling M., Scanlan T.S., Lundasen T., Webb P., Baxter J., Angelin B., Parini P. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc. Nat. Acad. Sci. USA 2005, 102:10297-10302.
22. Johnson S.M., Petrassi H.M., Palaninathan S.K., Mohamedmohaideen N.N., Purkey H.E., Nichols C., Chiang K.P., Walkup T., Sacchettini J.C., Sharpless K.B., Kelly J.W. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J. Med. Chem. 2005, 48:1576-1587.
23. Johnson S.M., Wiseman R.L., Sekijima Y., Green N.S., Adamski-Werner S.L., Kelly J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 2005, 38:911-921.
24. Julius R.L., Farha O.K., Chiang J., Perry L.J., Hawthorne M.F. Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores. Proc. Nat. Acad. Sci. USA 2007, 104:4808-4813.
25. Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W., Sacchettini J.C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7:312-321.
26. Lai Z., Colon W., Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996, 35:6470-6482.
27. Leslie A.G. Integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 1999, 55:1696-1702.
28. Leslie A.G. The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 2006, 62:48-57.
29. Lima L.M., Silva Vde A., Palmieri Lde C., Oliveira M.C., Foguel D., Polikarpov I. Identification of a novel ligand binding motif in the transthyretin channel. Bioorg. Med. Chem. 2010, 18:100-110.
30. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
31. Miyabara E.H., Aoki M.S., Soares A.G., Saltao R.M., Vilicev C.M., Passarelli M., Scanlan T.S., Gouveia C.H., Moriscot A.S. Thyroid hormone receptor-beta-selective agonist GC-24 spares skeletal muscle type I to II fiber shift. Cell Tissue Res. 2005, 321:233-241.
32. Morais-De-Sa E., Pereira P.J., Saraiva M.J., Damas A.M. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J. Biol. Chem. 2004, 279:53483-53490.
33. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 1997, 53:240-255.
34. Neumann P., Cody V., Wojtczak A. Structural basis of negative cooperativity in transthyretin. Acta Biochim. Pol. 2001, 48:867-875.
35. Oza V.B., Smith C., Raman P., Koepf E.K., Lashuel H.A., Petrassi H.M., Chiang K.P., Powers E.T., Sachettinni J., Kelly J.W. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 2002, 45:321-332.
36. Petrassi H.M., Johnson S.M., Purkey H.E., Chiang K.P., Walkup T., Jiang X., Powers E.T., Kelly J.W. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J. Am. Chem. Soc. 2005, 127:6662-6671.
37. Polikarpov I., Perles L.A., De Oliveira R.T., Oliva G., Castellano E.E., Garratt R.C., Craievich A. Set-up and experimental parameters of the protein crystallography beamline at the Brazilian National Synchrotron Laboratory. J. Synchrotron. Radiat. 1998, 5:72-76.
38. Quintas A., Saraiva M.J., Brito R.M. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J. Biol. Chem. 1999, 274:32943-32949.
39. Sebastiao M.P., Lamzin V., Saraiva M.J., Damas A.M. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J. Mol. Biol. 2001, 306:733-744.
40. Trivella D.B., Bleicher L., Palmieri Lde C., Wiggers H.J., Montanari C.A., Kelly J.W., Lima L.M., Foguel D., Polikarpov I. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. J. Struct. Biol. 2010, 170:522-531.
41. Villicev C.M., Freitas F.R., Aoki M.S., Taffarel C., Scanlan T.S., Moriscot A.S., Ribeiro M.O., Bianco A.C., Gouveia C.H. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J. Endocrinol. 2007, 193:21-29.
42. Wagner R.L., Apriletti J.W., Mcgrath M.E., West B.L., Baxter J.D., Fletterick R.J. A structural role for hormone in the thyroid hormone receptor. Nature 1995, 378:690-697.
43. Wagner R.L., Huber B.R., Shiau A.K., Kelly A., Cunha Lima S.T., Scanlan T.S., Apriletti J.W., Baxter J.D., West B.L., Fletterick R.J. Hormone selectivity in thyroid hormone receptors. Mol. Endocrinol. 2001, 15:398-410.
44. Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8:127-134.
45. Westermark P., Engstrom U., Johnson K.H., Westermark G.T., Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Nat. Acad. Sci. USA 1990, 87:5036-5040.
46. Wojtczak A., Luft J., Cody V. Mechanism of molecular recognition. Structural aspects of 3, 3′-diiodo-L-thyronine binding to human serum transthyretin. J. Biol. Chem. 1992, 267:353-357.
47. Wojtczak A., Cody V., Luft J.R., Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3′, 5′-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. Acta Crystallogr. D Biol. Crystallogr. 1996, 52:758-765.
48. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001, 81:1097-1142.
49. Zanotti G., D'acunto M.R., Malpeli G., Folli C., Berni R. Crystal structure of the transthyretin-retinoic-acid complex. Eur. J. Biochem. 1995, 234:563-569.